---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-008303"
form_type: "8-K"
ticker: "PVLA"
cik: "0001583648"
company_name: "PALVELLA THERAPEUTICS, INC."
filed_at: "2023-03-29T23:59:59+00:00"
generated_at: "2026-06-17T10:26:10.835044+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pieris Pharma reports FY2022 net loss $33.3M; cash down to $59.2M; elarekibep data delayed to mid-2024

## Summary
- Net loss $33.3M ($0.45/share) vs $45.7M ($0.71) in 2021; R&D expense fell to $53.0M from $66.7M.
- Cash, cash equivalents and investments $59.2M at Dec 31, 2022, down from $117.8M; company funded for >12 months.
- Elarekibep Phase 2a asthma data now expected mid-2024; AstraZeneca adding >100 sites to complete trial.
- PRS-220 Phase 1 IPF topline results expected H2 2023; PRS-400 advancing toward candidate nomination in 2023.
- Seagen initiated Phase 1 for SGN-BB228, triggering $5M milestone; Servier discontinued PRS-352.

## SEC filing metadata
- accession: 0001437749-23-008303
- form_type: 8-K
- ticker: PVLA
- cik: 0001583648
- company_name: PALVELLA THERAPEUTICS, INC.
- filed_at: 2023-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583648/000143774923008303/0001437749-23-008303-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583648/000143774923008303/pirs20221130_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-008303
- JSON: https://secwatch.observer/filing/0001437749-23-008303.json
- Plain text: https://secwatch.observer/filing/0001437749-23-008303.txt

## Key facts
- Earnings Releases
  PALVELLA THERAPEUTICS, INC. reported financial results for fiscal year ended December 31, 2022.
  - Period: fiscal year ended December 31, 2022
  - Result: reported results
  source text: reported financial results for the fiscal year ended December 31, 2022, and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583648/000143774923008303/0001437749-23-008303-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.